Magainin Pharmaceuticals Inc. plans to conduct a Phase IIIcomparative trial of its lead compound MSI-78 in patients withimpetigo (not diabetes) in late spring. The company does planto test the drug in diabetic ulcer patients at some point in thefuture but is first pursuing the impetigo trial.

BioWorld on Thursday misnamed Telios Pharmaceuticals Inc.'sresigning president and chief executive. It should have beenreported that Robert Erickson was resigning as of Jan. 4.

(c) 1997 American Health Consultants. All rights reserved.